SMA
NVO

Seven Mile Advisory’s Novo Nordisk NVO Stock Holding History

Seven Mile Advisory’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,245
Closed -$291K – 301
2025
Q3 		$291K Sell
5,245
-1,374
-21% -$80.4K 0.05% 209
2025
Q2 		$457K Buy
6,619
+545
+9% +$37.1K 0.27% 68
2025
Q1 		$422K Sell
6,074
-504
-8% -$41.6K 0.28% 72
2024
Q4 		$566K Sell
6,578
-843
-11% -$91.2K 0.36% 51
2024
Q3 		$884K Buy
7,421
+303
+4% +$40.4K 0.58% 31
2024
Q2 		$1.02M Sell
7,118
-25
-0.3% -$3.31K 0.75% 23
2024
Q1 		$917K Buy
7,143
+273
+4% +$32.5K 0.7% 26
2023
Q4 		$711K Buy
6,870
+202
+3% +$20K 0.62% 31
2023
Q3 		$606K Buy
6,668
+718
+12% +$63.2K 0.64% 33
2023
Q2 		$481K Buy
+5,950
New +$486K 0.56% 43

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Seven Mile Advisory's NVO Position: Q4 2025 in Review

Seven Mile Advisory sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 5,245 shares — an estimated $291K sold.

Seven Mile Advisory first reported a position in NVO in Q2 2023 and held it in 10 quarters. The position peaked at $1.02M in Q2 2024. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Seven Mile Advisory reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Seven Mile Advisory sold 5,245 Novo Nordisk shares in Q4 2025, an estimated $291K.
  • Seven Mile Advisory first reported a position in Novo Nordisk in Q2 2023 and held it in 10 quarters.
  • Seven Mile Advisory's Novo Nordisk position peaked at $1.02M in Q2 2024.
  • 1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Seven Mile Advisory's 13F filing for Q4 2025, filed 13 Feb 2026.